Protalix Biotherapeutics Inc (PLX) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Protalix Biotherapeutics inc   (NYSEAMER: PLX)


Protalix Biotherapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Protalix Biotherapeutics Inc 's ROA in the second quarter of 2026?
Protalix Biotherapeutics inc achieved a return on average assets (ROA) of 20.09 % in its second quarter of 2026, this is above PLX's average return on assets of -18.96%.
Protalix Biotherapeutics Inc assets over the 12 months ending in its second quarter of 2026 are valued at $94 million

Despite the company's net income deteriorating, Protalix Biotherapeutics Inc was able to improve its ROA compared to the first quarter of 2026.

However, within the Healthcare sector 49 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 278, from total ROA ranking in the first quarter of 2026 at 3667.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 40.58 % 38.49 % 19.12 % 41.68 % -10.31 %
Y / Y Net Income Change 2203.05 % - - -27.22 % -
Net Income (TTM) in million 19 15 -7 5 6
Return On Assets (TTM) 20.09 % 17.75 % -8.33 % 7.1 % 8.98 %
PLX's Total Ranking # 278 # 3667 # 883 # 718 # 1155
Total Assets (TTM) in million 110 102 82 82 78
Seq. Total Assets Change 7.82 % 24.28 % 0.1 % 4.81 % 6.22 %
Seq. Net Income Change -79.38 % - - 1335.98 % -

PLX's 5 Years Annual ROA >> Back to PLX Management Effectiveness >> Compare PLX ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 9
Sector # 50
Overall # 227

Return On Assets Statistics
High Average Low
78.76 %
-18.96 %
-129.15 %
(Dec 31 2015)   (Dec 31 2017)





Financial Statements
Protalix Biotherapeutics Inc 's Assets $ 110 million PLX's Balance sheet
Protalix Biotherapeutics Inc 's Income $ 4 million Quarterly PLX's Income Statement
PLX's Income by Division See PLX's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 19.12 % -15.11 % 60.62 % -26.21 % 10.16 %
Total Assets in million 82 69 81 51 69
Y / Y Net Income Change - -64.73 % - - -
Net Income in million -7 3 8 -15 -28
Annual Return On Assets -8.02 % 4.24 % 10.21 % -29.44 % -40.15 %

PLX's 5 Years Annual ROA >> Back to PLX Management Effectiveness >> Compare PLX ROA to its Competitors



More Return On Assets Ratios
PLX's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PLX's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PLX's Competitors
Subscribers only: Roa for Protalix Biotherapeutics Inc 's Suppliers
Subscribers only: Return On Assets for PLX's Customers

You may also want to know
PLX's Roi PLX's Inventory Turnover Ratio PLX's Growth Rates PLX's Dividend Comparisons
PLX's Profitability Ratios PLX's Asset Turnover Ratio PLX's Dividend Growth
PLX's Roe PLX's Valuation Ratios PLX's Financial Strength Ratios PLX's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Atlantic Coastal Acquisition Corp Ii  54.09 %
Lensar Inc   47.48 %
Elite Pharmaceuticals Inc   46.11 %
Omeros Corporation  46.05 %
Q32 Bio Inc   45.18 %
Aurinia Pharmaceuticals Inc   44.95 %
Agenus Inc  44.86 %
Earth Science Tech Inc   44.02 %
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %
Tg Therapeutics Inc   33.59 %
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %

Date modified: 2026-09-04T10:37:32+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.